Calcium Levels in Tumor Lysis Syndrome
In tumor lysis syndrome, calcium levels DROP (hypocalcemia), occurring as a secondary consequence of hyperphosphatemia when released phosphate binds with serum calcium to form calcium-phosphate complexes that deposit in tissues and kidneys.
Pathophysiology of Hypocalcemia in TLS
When massive tumor cell lysis occurs, intracellular phosphate floods into the bloodstream causing severe hyperphosphatemia. This excess phosphate binds with circulating calcium, forming calcium-phosphate precipitates that deposit in the renal interstitium and tubular system 1. This mechanism directly causes:
- Decreased ionized serum calcium (hypocalcemia)
- Worsening kidney damage from calcium-phosphate crystal deposition
- Potential life-threatening complications if symptomatic
Hypocalcemia is one of the four cardinal metabolic abnormalities defining laboratory TLS, alongside hyperkalemia, hyperphosphatemia, and hyperuricemia 2, 3, 4, 5, 6, 7, 8, 9.
Clinical Manifestations
Hypocalcemia in TLS can present with:
- Tetany (muscle spasms, carpopedal spasm)
- Seizures
- Cardiac arrhythmias
- Neuromuscular irritability
- Paresthesias
These symptoms typically occur within 12-72 hours after initiation of cytoreductive therapy 2.
Management Algorithm for Hypocalcemia in TLS
Asymptomatic Hypocalcemia
Do NOT treat asymptomatic hypocalcemia 1.
This is a critical pitfall to avoid: administering calcium when phosphate levels are elevated can worsen calcium-phosphate precipitation in tissues and kidneys, exacerbating renal damage.
Symptomatic Hypocalcemia
Only treat when symptoms are present (tetany, seizures):
- Administer calcium gluconate 50-100 mg/kg as a single IV dose 1
- Infuse cautiously and repeat only if necessary
- Monitor closely for worsening hyperphosphatemia and calcium-phosphate deposition
Severe Cases Requiring Dialysis
When hypocalcemia persists despite management or is associated with severe hyperphosphatemia and renal failure:
- Initiate renal replacement therapy (hemodialysis or continuous renal replacement therapy)
- Dialysis effectively removes phosphate and corrects hypocalcemia 1
- Consider dialysis when recurrent symptomatic hypocalcemia requires continuous calcium gluconate infusion 3
Key Clinical Pitfalls
Never give prophylactic calcium in TLS. The presence of severe hyperphosphatemia makes calcium administration dangerous, as it promotes tissue calcification and worsens kidney injury. The consensus guidelines from both the Journal of Clinical Oncology and Haematologica are unequivocal on this point 1.
Address the root cause first: Manage hyperphosphatemia aggressively with:
- Phosphate binders (aluminum hydroxide 50-100 mg/kg/day divided in 4 doses) for mild hyperphosphatemia (<1.62 mmol/L) 1
- Aggressive hydration to maintain urine output ≥100 mL/hour (or 3 mL/kg/hour in children <10 kg) 1
- Early dialysis for severe hyperphosphatemia
As phosphate levels normalize through these interventions, calcium levels will typically correct without direct calcium supplementation.